Insurance coverage and access

In the United States, Medicare insurance covers some of the cost of lecanemab or other anti-amyloid treatments. But some conditions must be met. You must have:

• Diagnosed early or mild Alzheimer's.
• Symptoms of cognitive decline.
• Confirmed amyloid-beta proteins in the brain.

Also, your healthcare professional must submit your information to a data registry. This process is part of Medicare's coverage-with-evidence development (CED) program. This program helps track the effects of medicines such as lecanemab.